Thiopental Sodium

Phase 1Small molecule

MMemorial Sloan Kettering Cancer Center

Thiopental Sodium is one of 7 small molecule programs targeting Amnesia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AmnesiaActive, not recruiting

AmnesiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Amnesia

#DrugCompanyPhaseTrials

Crestor

AstraZeneca

Approved

—2

Versed

CConrado Roberto Hoffmann Filho

Approved

—3

Dexmedetomidine Hydrochloride

Pfizer

Phase 1

1 4

Psilocybin

COMPASS Pathways

Phase 1

—5

Midazolam Hydrochloride

Boehringer Ingelheim

Phase 1

1 6

Thiopental Sodium

MMemorial Sloan Kettering Cancer Center

Phase 1

1 7

Verorab

Sinovac Biotech Co., Ltd

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Amnesia1 trial

Effect of Affective Content on Drug Induced Amnesia of Episodic Memory

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00142493·79 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Thiopental Sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Thiopental Sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Thiopental Sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Memorial Sloan Kettering Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMemorial Sloan Kettering Cancer Center

Thiopental Sodium

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Amnesia1 trial

References

Drug Info

Quick Facts

Related News